ArticleBritish journal of cancer2010
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 106 citations in OpenAlex.
- A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study.PloS one · 2015Trial
- Chimeric antigen receptor cells as a tool for localized delivery of TNFα in solid cancer treatment.Human vaccines & immunotherapeutics · 2025Review
- Dual-Functional Amine-Modified Aluminum-Doped MCM-41 Nanoparticles for Concurrent Zoledronic Acid Adsorption and Geranylgeraniol Delivery for Prevention of Medication-Related Osteonecrosis of the Jaw.ACS materials Au · 2025Article
- The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets.Discover oncology · 2024Review
- Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1.Journal of medicinal chemistry · 2023Article
- Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.Biomaterials research · 2023Article
- Immune-related risk score: An immune-cell-pair-based prognostic model for cutaneous melanoma.Frontiers in immunology · 2023Article
- Article
- HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells.Cancers · 2022Article
- pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Review
- Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy.Journal for immunotherapy of cancer · 2021Review
- Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis.Cells · 2021Review
- Review
- Review
- The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment.Frontiers in immunology · 2021Review
- Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing.Journal of clinical medicine · 2020Review
- MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation.Frontiers in immunology · 2019Review
- Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.Drug delivery and translational research · 2018Article
- Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper efficacy of antitumour therapies. The amino-bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent studies showed that ZA prolongs disease-free survival in cancer patients. The exact mechanism is a topic of debate; it has been suggested that ZA targets tumour-associated macrophages (TAMs).
methodsWe investigate the role of ZA on the myeloid differentiation to TAMs in murine mesothelioma in vivo and in vitro. Mice were intraperitoneally inoculated with a lethal dose of mesothelioma tumour cells and treated with ZA to determine the effects on myeloid differentiation and survival.
resultsWe show that ZA impaired myeloid differentiation. Inhibition of myeloid differentiation led to a reduction in TAMs, but the number of immature myeloid cells with myeloid-derived suppressor cell (MDSC) characteristics was increased. In addition, ZA affects the phenotype of macrophages leading to reduced level of TAM-associated cytokines in the tumour microenvironment. No improvement of survival was observed.
conclusionWe conclude that ZA leads to a reduction in macrophages and impairs polarisation towards an M2 phenotype, but this was associated with an increase in the number of immature myeloid cells, which might diminish the effects of ZA on survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.